Sodium–glucose cotransporter 2 (SGLT-2) inhibitors have emerged as a promising class of drugs for the management of chronic heart failure and have become a cornerstone of guideline-recommended pharmacological therapy [2, 9]. Here, SLC5A2 is linked to congestive heart failure.